Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families
Maria Gnarra Buethe, Tyler Sy, Lawrence F. Eichenfield · 2026
Read Safety of Dupilumab and Risk of Cutaneous T‐Cell Lymphoma in Pediatric Patients With Atopic Dermatitis: A Data‐Driven Guide to Counseling Patients and Families by Maria Gnarra Buethe, Tyler Sy, Lawrence F. Eichenfield (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13423122.txt.
Description
Maria Gnarra Buethe and colleagues offer an advice guide in 2026 on dupilumab safety and lymphoma worry for children with eczema. Reports linking the eczema drug to cutaneous T-cell lymphoma, amplified by media coverage, have fueled parent worry. Infant approval in 2022 means the longest exposures now span only three to four years.
The guide reviews long-term extension data, untangles eczema from early lymphoma, which can look alike, and sets out monitoring and advice steps. Pediatric teams gain a data-driven script for answering families who fear trading eczema relief for lymphoma risk.
Catalog record
| CREATOR | Maria Gnarra Buethe, Tyler Sy, Lawrence F. Eichenfield |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 24 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |